
New Products - May 2023






Enhancer of zeste homolog 2 (EZH2), as one of the most well-characterized epigenetic regulators, is the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2) which functions to silence target genes by tri-methylating lysine 27 of histone H3 (H3K27me3)^[1]. EZH2 plays a critical function in development and adult tissue homeostasis, and is closely associated with many diseases. Studies have found that EZH2 is highly expressed in a variety of solid tumors and hematological malignancies and is closely related to tumor proliferation, invasion, metastasis and poor prognosis. Therefore, EZH2 provides a pharmacological target for cancers. In addition, EZH2 also plays important roles in auto-immune diseases and other disorders. Together, there is a high need for small molecules that inhibit the activity of EZH2. To date, three EZH2 inhibitors have been approved and more than nine EZH2 inhibitors have entered into clinical trials^[2-10].



- [1] European Journal of Medicinal Chemistry (2022), 238, 114419.
- [2] Journal of Medicinal Chemistry (2023), 66, 3, 1725-1741.
- [3] Journal of Medicinal Chemistry (2021), 64, 17, 12630-12650.
- [4] Journal of Medicinal Chemistry (2021), 64, 14, 10167-10184.
- [5] Journal of Medicinal Chemistry (2018), 61, 3, 650-665.

[6] ACS Medicinal Chemistry Letters (2020), 11, 6, 1205-1212. [7] Journal of Medicinal Chemistry (2021), 64, 12, 8194-8207. [8] ACS Medicinal Chemistry Letters (2018), 9, 2, 98-102. [9] Nature Cell Biology (2022), 24, 384-399. [10] WO2022033492A1.





ChemScene's products are used for scientific research only.We do not provide products or services for any personal used.

We respect your privacy and do not share or sell your information to third parties.

If you no longer wish to receive these emails you may unsubscribe at any time.